A Phase 3 study to evaluate weight gain of investigational medication compared to olanzapine in adults with schizophrenia
This study will evaluate weight gain of ALKS 3831 compared to olanzapine in adult subjects with schizophrenia.
All study-related exams, tests, procedures and medication will be provided free of charge. Reasonable compensation for time and travel may be provided.
Clinical Study Identifier | TX145489 |
---|---|
Sponsor | Alkermes Inc. |
Last Modified on | 23 November 2020 |
,
You have contacted , on
Your message has been sent to the study team at ,
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreEvery year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Congrats! You have your own personal workspace now.